Last reviewed · How we verify
arginine vasopressin
Arginine vasopressin, marketed by the University of Miami, is a well-established drug with a key composition patent expiring in 2028. Its primary strength lies in its long-standing market presence and established use. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | arginine vasopressin |
|---|---|
| Also known as | Vasopressin, Antidiuretic Hormone (ADH), Pitressin (US brand name), Pressyn;Pressyn AR (Canadian brand names), Argipressin |
| Sponsor | University of Miami |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial (PHASE2)
- Early Versus Late Adjunctive Vasopressin in Septic Shock (PHASE4)
- Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair (PHASE2)
- Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- arginine vasopressin CI brief — competitive landscape report
- arginine vasopressin updates RSS · CI watch RSS
- University of Miami portfolio CI